Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof

ABSTRACT

A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer&#39;s disease, Parkinson&#39;s disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle.

REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. patent application, Ser. No.10/829,940, filed Apr. 23, 2004 (which published as US 2005/0239807 onOct. 27, 2005), now U.S. Pat. No. 7,067,659.

TECHNICAL FIELD

This invention is directed to agent and method for treatment ofdisorders characterized by increased production of reactive oxygenspecies and insufficient production of nitric oxide.

BACKGROUND OF THE INVENTION

Current treatments of heart failure could use improvement.

An imbalance between left ventricle performance and myocardial oxygencoupling, which has been denoted mechanoenergetic uncoupling has beenrecognized as leading to cardiac insufficiency; conventional drugs fortreatment of heart failure do not reverse this phenomenon. It has beenshown that allopurinol and its metabolite oxypurinol may reverse thisphenomenon.

It has not been previously appreciated that in disorders associated withoxidative stress, whereas allopurinol or oxypurinol may eliminate orreduce reactive oxygen species, they and compounds like them do notreduce an independent nitric oxide depletion effect, which, moreover,may be more than additive.

SUMMARY OF THE INVENTION

It has been discovered herein that in disorders associated withoxidative stress, there is an independent nitric oxide depletion effect.

One embodiment of the invention herein, denoted the first embodiment, isdirected to an inhibitor of a reactive oxygen generating enzyme whichincludes a group providing nitric oxide (NO) donor bioactivity which isnot a C-nitroso compound or an inhibitor of a cyclooxygenase.

Another embodiment of the invention herein, denoted the secondembodiment, is directed to a method for treating a patient with adisorder associated with oxidative stress, comprising administering tothat patient a therapeutically effective amount of the inhibitor of thefirst embodiment.

Another embodiment of the invention herein, denoted the thirdembodiment, is directed to a method for treating an ischemic disorder ina patient having such disorder, comprising administering to that patientan amount of the inhibitor of the first embodiment herein effective tomediate conservation of oxygen and vasodilation.

Another embodiment of the invention herein, denoted the fourthembodiment, is directed to a method for providing appropriate oxygenutilization in a patient in need thereof, comprising administering tothat patient a therapeutically effective amount of the inhibitor of thefirst embodiment.

As used herein, the term “reactive oxygen” includes superoxide,hydroperoxide, other peroxides, peroxynitrite, alkoxides, hydroxylradical and reactive nitrogen species.

As used herein, the term “providing NO donor bioactivity” meansgenerating activity associated with NO or a related congener, e.g.,dilation of a blood vessel or increased cGMP.

The term “appropriate oxygen utilization” as used in the description ofthe fourth embodiment, means so as not to cause pathological increase inenergy or oxygen use and/or pathological increase in radical or activeoxygen species formation.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1( a) is a graph of sacomere length (% change from baseline) forbaseline, allopurinol administration and nitrated allopurinoladministration and depicts results of Background Example 1.

FIG. 1( b) is a graph of Systolic Calcium Transient (% change frombaseline) for baseline, allopurinol administration and nitratedallopurinol administration and depicts results of Background Example 1.

DETAILED DESCRIPTION

We turn now to the first embodiment of the invention herein, which isdirected to an inhibitor of a reactive oxygen generating enzyme whichincludes a group providing NO donor bioactivity which is not a C-nitrosocompound or an inhibitor of a cyclooxygenase. The term “reactive oxygengenerating enzyme” as used herein, excludes nitric oxide synthase.

The reactive oxygen generating enzymes include, for example, xanthineoxidase, epoxygenase, NADPH oxidase, aldehyde dehydrogenase, aldehydeoxidase, lipoxygenase, cytochrome p450 reductase, heme oxygenase, otheroxygenases and oxidases and complex 1 and complex 3.

Inhibitors of xanthine oxidase include, for example allopurinol,oxypurinol, pterin-6-aldehyde and 6-formylpterin.

Inhibitors of epoxygenase include, for example, nordihydroguaiareticacid, 17-octadecynoic acid, miconazole and ketoconazole.

Inhibitors of NADPH oxidase include, for example, diphenyl iodoniumchloride or sulfate and apocynin.

Inhibitors of aldehyde dehydrogenase include, for example, bentomyl,disulfiram, phenethyl isothiocyanate and cyanamide.

Inhibitors of aldehyde oxidase include, for example, cimetidine,menadione and isovanillin.

Inhibitors of lipoxygenase include, for example, CV6504, ABT761,zileuton, linoleyl hydroxamic acid and panaxynol.

Inhibitors of cytochrome P450 reductase include mersalyl and diphenyleneiodonium.

Inhibitors of heme oxygenase include, for example, pegylated zincprotoporphyrin, Co (III) protoporphyrin, Sn protoporphyrin and tinmesoporphyrin.

Inhibitors of complex 1 include, for example, retenone and MPTP.

Inhibitors of complex 3 include, for example, antinycin and 11-QoI MET.

The above inhibitors are furnished with NO donor bioactivity group, forexample, by providing a nitrate group thereon, e.g., by forming anitrate esters, or by providing a nitroso group thereon. The nitro ornitroso group is added to an area of the inhibitor that does notdiminish binding to the target beyond an effective amount. One simplemethod of introducing this moiety is alkylation of any acidic site onthe inhibitor by deprotonation and treatment with an alkyl halide. Forexample, a moiety containing a nitrate ester group can be substituted atthe imido group of an inhibitor of a reactive oxygen generating enzymeby reacting 1-chloro-3-iodopropane in the presence of cesium carbonate.The resulting chloropropyl moiety is converted sequentially to aniodopropyl moiety and a nitrooxypropyl moiety by treatment with sodiumiodide followed by silver nitrate in anhydrous CH₃CN. Other donors ofnitric oxide, including alkyl nitrites, thionitrites and C-nitrosocompounds, can be added through an analogous set of manipulations; suchchemistry is well-known in the literature.

A preferred inhibitor is the nitrated xanthine oxidase inhibitornitrated allopurinol derivative which is1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-oneand has the formula:

Nitrated allopurinol (16) can be prepared, for example, as described inWorking Example I herein.

We turn now to the second embodiment of the invention herein, which isdirected a method of treating a patient with a disorder associated withoxidative stress, comprising administering to that patient atherapeutically effective amount of an inhibitor of the first embodimentherein.

The term “associated with oxidative stress” as used in the aboveparagraph means a hazardous level of reactive oxygen species.

The disorders associated with oxidative stress for the second embodimentherein include heart failure, stable angina, ischemic reperfusioninjury, sickle cell disease, diabetes, Parkinson's Disease, ALS, AIDSdementia, stroke, neuropathic pain, Alzheimer's disease, lung injury,cystic fibrosis and asthma.

As indicated above, the treating agents for the second embodiment arethe inhibitors of the first embodiment.

The therapeutically effective amount for the second embodiment is anamount which mediates amelioration of symptoms of the disorder treated.Where the disorder is heart failure, the therapeutically effectiveamount is an amount which mediates amelioration of acute coronarysymptoms and/or myocardial infarction. Where the disorder is stableangina, the therapeutically effective amount is an amount which mediatesreduction or elimination of pain. Where the disorder is ischemicreperfusion injury, the therapeutically effective amount is an amounteffective to mediate symptoms of pain, organ damage and/or arrhythmia(symptoms can be variable). Where the disorder is sickle cell disease,the therapeutically effective amount is an amount which mediates redcell vasodilation and amelioration of pain, organ damage, lack of bloodflow or pathological clotting. Where the disorder is atherosclerosis,the therapeutically effective amount is an amount which amelioratessymptoms of hyperlipidemia. Where the disorder is Parkinson's disease,the therapeutically effective amount is an amount that stabilizes motoror tremor function. Where the disorder is ALS, the therapeutic amount isan amount that slows deterioration. Where the disorder is stroke, thetherapeutically effective amount is an amount that decreases infarctsize or improves symptoms. Where the disorder is Alzheimer's disease,the therapeutically effective amount is an amount that slows memoryloss.

In general, the amount administered daily ranges from 1 to 1,000 mg withselection within the range being determined by the drug administered,the disorder being treated and the severity of symptoms. For nitratedallopurinol (16), amount administered on a daily basis ranges, forexample, from 100 to 800 mg with from 200 to 700 mg/day being preferredfor treatment of heart failure and from 200 to 700 mg/day beingpreferred for treatment of stable angina and 300 mg/day being an averagedose.

Suitable routes of administration for the second embodiment include, forexample, oral administration.

We turn now to the third embodiment of the invention herein, which isdirected at a method of treating an ischemic disorder in a patienthaving such disorder, comprising administering to that patient an amountof inhibitor of the first embodiment effective to mediate conservationof oxygen and vasodilation.

The disorders treated in the third embodiment include, for example,sickle cell disease, heart failure, angina and lung inflammation.

Mediation of conservation of oxygen is manifested by improved symptoms,change in NADH to NADPH ratio, change in tissue oxygen concentration,change in tissue pH or change in oxygen to ATP utilization ratio.

Mediation of vasodilation is manifested by change in blood flow, bloodpressure or symptoms.

As indicated above, the treating agents are those of the firstembodiment herein; nitrated allopurinol (16) is a preferred treatingagent.

Effective amounts of treating agents for the third embodiment generallyrange from 1 to 1,000 mg on a daily basis with the amounts for nitratedallopurinol (16) generally ranging from 100 to 800 mg on a daily basis,preferably from 200 to 700 mg on a daily basis, with selected amountswithin the general range depending on the treating agent used, thedisorder treated and the severity of the symptoms.

Routes of administration for the third embodiment include, for example,oral.

We turn now to the fourth embodiment herein, which is directed to amethod of providing contraction of heart, skeletal or smooth musclematched to appropriate oxygen utilization in a patient in need thereof,comprising administering to that patient a therapeutically effectiveamount of inhibitor of the first embodiment.

The patients in need of contraction of heart muscle matched toappropriate oxygen utilization include those, for example, with heartfailure. The patients in need of contraction of skeletal muscle matchedto appropriate oxygen utilization, include, for example, patients withskeletal muscle weakness or respiratory failure. The patients in need ofcontraction of smooth muscle matched to appropriate oxygen utilizationare those, for example, with angina.

As indicated above, the treating agents for the fourth embodiment hereinare those of the first embodiment; nitrated allopurinol (16) is thepreferred treating agent for the fourth embodiment.

Therapeutically effective amount of treating agent for the fourthembodiment is an amount which ameliorates pathological increase inenergy or oxygen consumption or pathological increase in radicalformation. The pathological increase in energy consumption is determinedby determining amounts or ratios of oxygen to ADP or phosphocreatine orNADH to NADPH, the pathological increase in oxygen consumption beingdetermined by determination of increase in reactive oxygen products orincrease or decrease in venous oxygen gradient or organ dysfunction andthe pathological increase in radical formation being determined byincreased reactive oxygen production as measured using various standardapproaches.

In general, therapeutic amounts for the treating agents for the fourthembodiment range from 1 to 1,000 mg on a daily basis and therapeuticamount for nitrated allopurinol (16) generally ranges from 100 to 800 mgon a daily basis preferably ranging from 200 to 700 mg on a daily basis,with particular amounts within the general range selected varying withtreating agent, disorder treated and severity of symptoms. Routes ofadministration for the fourth embodiment include, for example, oral.

The invention herein is supported by and illustrated by the followingbackground and working examples.

WORKING EXAMPLE I Synthesis of Nitrated Allopurinol (16)1,5-Bis(3-chloropropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one(14)

To a stirred mixture of 6 (allopurinol, lactam form) (4.08 g, 30 mmol)in anhydrous DMF (60 mL) was added cesium carbonate (11.73 g, 36 mmol)at 0° C. in one portion. 1-Chloro-3-iodopropane 13 (3.22 mL, 30 mmol)was then added within 1 min, and the whole mixture was stirred at 0° C.for 10 h, and then warmed to the ambient temperature with stirring foradditional 12 h. The resulting white suspension was poured into ice-coldH₂O (200 mL), extracted with EtOAc (500 mL), washed with brine (3×60 mL)and dried. The crude products were purified by flash chromatography(eluting with 40-75% EtOAc in hexane) to give 14 (2.35 g, 27% yield) asa white solid. ¹H NMR (300 MHz, CDCl₃): δ2.26 (m, 2H), 2.36 (m, 2H),3.52 (t, 2H, J=6.0 Hz), 3.55 (t, 2H, J=6.6 Hz), 4.15 (t, 2H, J=6.9 Hz),4.48 (t, 2H, J=6.9 Hz), 7.99 (s, 1H), 8.05 (s, 1H); ³C NMR (75 MHz,CDCl₃): δ31.61, 32.60, 41.79, 41.94, 44.35, 44.82, 106.02, 135.36,149.21, 151.75, 157.23.

1,5-Bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one(16)

Sodium iodide (1.8 g, 12 mmol) was added to a solution of 14 (0.90 g,3.1 mmol) in anhydrous acetone (30 mL), and the solution was then heatedat reflux for 8 h, resulting in a light-green suspension. After cooledto rt, the suspension was filtered off, and the filtrate was condensedto dryness. The solid residue was suspended in CH₂Cl₂ (60 mL), filteredoff again, and the filtrate was condensed to dryness, pumped for 30 min,giving crude di-iodide 15 (1.36 g) as a white solid.

To a stirred solution of the crude di-iodide 15 (1.21 g) in anhydrousCH₃CN (20 mL) was added silver nitrate (1.53 g, 9 mmol), and stirred atrt for 15 h, resulting in a yellow suspension. The suspension wasfiltered off, rinsing with EtOAc, and the filtrate was diluted withEtOAc (300 mL), washed with H₂O (2×50 mL), and dried. The crude productswere purified by flash chromatography (eluting with 50% EtOAc inhexane), affording an unidentified compound (0.27 g, white solid),followed by di-nitrate 16 (0.17 g, ˜20% yield) as a white solid. The NMRspectral data for 16 are given as follow: ¹H NMR (400 MHz, CDCl₃): δ2.19(m, 2H), 2.27 (m, 2H), 4.06 (t, 2H, J=7.2 Hz), 4.40 (t, 2H, J=6.0 Hz),4.38 (t, 2H, J=6.6 Hz), 4.47 (t, 2H, J=6.0 Hz), 7.89 (s, 1H), 8.01 (s,1H); ¹³C NMR (100 MHz, CDCl₃): δ26.99, 27.08, 43.65, 43.82, 70.02,70.19, 105.93, 135.60, 149.06, 151.84, 157.19; FAB-MS: m/z 343 ([M+1]⁺,85).

BACKGROUND EXAMPLE I

Isolated cardiac myocytes from NNOS deficient rats (known to haveincreased xanthine oxidase activity), were evaluated for responses atbaseline (BL or bl), then to allopurinol, then to nitrated allopurinol.The concentration of allopurinol used was 0.5×10⁻³M. The concentrationof nitrated allopurinol used was 10⁻⁴M. Evaluation was carried out forsarcomere length (SL), a measure of myocardial contraction, and forsystolic calcium transient which drives myocardial contraction. Theresults for evaluation of sarcomere length are shown in FIG. 1A andresults for evaluation of systolic calcium transient are shown in FIG.1B. As shown in FIGS. 1A and 1B, these parameters are shown to rise inparallel, with increase obtained for nitrated allopurinol being greaterthan increase obtained for allopurinol (not nitrated). The data showsthe drugs augment myocardial contractibility, at the level ofexcitation-contraction coupling.

WORKING EXAMPLE II

A 27-year old black female presents with a dilated cardiomyopathy and isbegun on a standard regimen including ace inhibitors, diuretics, anddigoxin with little improvement. She is begun on nitrated allopurinol(16), 300 mg PO BID, with improvement of left ventricular function and adecrease in a shortness of breath over the ensuing week.

WORKING EXAMPLE III

A 70-year old white female with class 3 angina is begun on nitratedallopurinol (16), 300 mg/day. Her classification improved to class 2over two weeks.

WORKING EXAMPLE IV

A 55-year old white male has a crush wound to his left lower extremityand undergoes emergency surgery. Because the wound has been ischemic forsix hours, the patient was begun on nitrated allopurinol (16) and showsno aggravation of injury following revascularization.

WORKING EXAMPLE V

A 30-year old black male with sickle cell disease presents withpulmonary hypertension and LFT abnormalities. He had had four admissionsto the emergency in the past year with painful crisis. He is begun n 300mg/day of nitrated allopurinol (16) with a decrease in his pulmonaryartery pressure over the following year from a mean of 35 mm Hg to 30 mmHg. His LFT abnormalities resolve and he has only one painful crisis.

WORKING EXAMPLE VI

A 45-year old white male with hyperlipidemia and a family history ofpremature coronary disease shows extensive calcification of hiscoronaries and aorta by MRI and coronary exam. He is begun on nitratedallopurinol (16), 300 mg/day, with mild regression of his disease overthe following two years.

WORKING EXAMPLE VII

A 48-year old white male with bleomycin-induced lung injury is begun onnitrated allopurinol (16), 300 PO BID. The pO₂ improves from 60 (on 100%oxygen) to 65 mm Hg on 50% oxygen over the following week.

WORKING EXAMPLE VIII

Working Example III provides an example of conservation of oxygencombined with vasodilation. Working Example V provides an example ofvasodilation.

WORKING EXAMPLE IX

A 60-year old with congestive heart failure and a dilated cardiomyopathyis begun on nitrated allopurinol (16), 300 mg POQD. One week later, hisejection fraction had improved from 35% to 40%, his blood pressure haddecreased from 130/80 to 110/80, and his pO₂ has improved from 70 to 80mm Hg on room air. Symptoms on angina had also decreased.

WORKING EXAMPLE X

A 70-year old with Parkinson's disease treated with L-dopa haspersistent tremor and motor problems. After three weeks of nitratedallopurinol (16), 300 mg/day, symptoms improve.

WORKING EXAMPLE XI

A 65-year old with Alzheimer's disease is begun on 300 mg/day nitratedallopurinol (16). His memory and cognitive function stabilizes after 3months.

WORKING EXAMPLE XII

A 75-year old with leg pain and diabetes, who is unresponsive totreatment, is begun on nitrated allopurinol (16), 300 mg/day, and thedistance he can walk improves and pain decreases.

WORKING EXAMPLE XIII

A 35-year old with ALS with progressive deterioration, stabilizes afterthree weeks at 300 mg/day of nitrated allopurinol (16).

WORKING EXAMPLE XIV

A 40-year old asthmatic with frequent exacerbations is begun on 300mg/day nitrated allopurinol (16). Steroid use is successfully tapered.

Variations

Variations will be obvious to those skilled in the art. Therefore, thescope of the invention is defined by the claims.

1. A method of treating a patient with a disorder associated withoxidative stress which is ischemic reperfusion injury, comprisingadministering to that patient a therapeutically effective amount of1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one.2. The method of claim 1 where the administration is in an amount tomediate amelioration of symptoms of pain, organ damage and/or arrythmia.3. The method of claim 1 where the1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-oneis administered orally on a daily basis in an amount ranging from 100 to800 mg/day.